◀ Back to ABL1

ABL1 — DCC

Text-mined interactions from Literome

Chan et al., Cancer Cell 2011 (Leukemia, Myelogenous, Chronic, BCR-ABL Positive...) : DCC-2036 inhibits BCR-ABL1 ( T315I ) -expressing cell lines, prolongs survival in mouse models of T315I mutant CML and B-lymphoblastic leukemia, and inhibits primary patient leukemia cells expressing T315I in vitro and in vivo, supporting its clinical development in TKI-resistant Ph ( + ) leukemia
Eide et al., Cancer Res 2011 (Leukemia, Myelogenous, Chronic, BCR-ABL Positive) : This critical gap in resistance coverage drove development of DCC-2036 , an ABL inhibitor that binds the switch control pocket involved in conformational regulation of the kinase domain